Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovary Cancer
Cervix Cancer
Endometrium Cancer
Bladder Cancer
Prostate Cancer (CRPC)
Esophagus Cancer
Lung Cancer(NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

DRUG: Tisotumab Vedotin (HuMax-TF-ADC)

Sponsor

Seagen Inc.

Collaborators

[object Object]